A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 8 sites in India. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 13th largest by enrollment, is one of 2 that started in 2023, is one of 14 in phase 3, and was the 15th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2023.
This study's enrollment of 405 is close to the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 36th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2023, is one of 33 in phase 3, and was the 63rd registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety and immune response of 20vPnC in adults in India.
This study is seeking participants who:
The study will have 2 groups based on age. One group will have particpants between 18 to 49 years of age. The other group will have participants of 50 years or older.
Participants will take part in the study for about one month which includes two visits to the study clinic. Participants will receive a single dose of study vaccine (20vPnC) into the arm at visit 1 and will come to study site for a follow-up visit after about a month.
The study team will ask questions about the participant's health and blood samples will be taken in a subset of participants during the visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pneumococcal conjugate vaccine (20vPnC)
Biological: 20-valent pneumococcal conjugate vaccine
One dose of 20vPnC will be administered intramuscularly.
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Local reactions (redness, swelling, and injection site pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units where 1 caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0 cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events included: fever, fatigue, headache, joint pain and muscle pain. Fever was defined as an oral temperature of more than or equal to (\>=)38.0 degree Celsius (C) and was classified as \>=38.0 degree C, \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, joint pain and muscle pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With Adverse Events (AEs) From Vaccination to 1 Month After Vaccination
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.
Time frame: From vaccination on Day 1 up to 1 Month after vaccination
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination to 1 Month After Vaccination
An SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event.
Time frame: From vaccination on Day 1 up to 1 Month after vaccination
Geometric Mean Fold Rise (GMFR) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers From Before Vaccination to 1 Month After Vaccination
GMFRs and 2-sided 95% confidence interval (CIs) were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ in the analysis. Evaluable immunogenicity population: Eligible participants in the immunogenicity subset who received 1 dose of the intervention with at least 1 valid immunogenicity result from the blood sample collection within 27 to 49 days after vaccination, had no other major protocol deviations as determined by the clinician.
Time frame: From before vaccination to 1 Month after vaccination
A total of 405 participants signed the informed consent form. Two participants were screen failures and 3 were not assigned to receive study treatment and 400 participants received study treatment.
| Milestone | Cohort 1: 18 to 49 Years | Cohort 2: >=50 Years |
|---|---|---|
| Started | 200 | 200 |
| Completed | 200 | 200 |
| Not completed | 0 | 0 |
Local reactions (redness, swelling, and injection site pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units where 1 caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0 cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.
| Percentage of participants | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years |
|---|---|---|
| Redness: Any | 1.0 (0.1 to 3.6) | 1.0 (0.1 to 3.6) |
| Redness: Mild | 0.0 (0.0 to 1.8) | 0.5 (0.0 to 2.8) |
| Redness: Moderate | 0.5 (0.0 to 2.8) | 0.5 (0.0 to 2.8) |
| Redness: Severe | 0.5 (0.0 to 2.8) | 0.0 (0.0 to 1.8) |
| Swelling: Any | 1.5 (0.3 to 4.3) | 1.5 (0.3 to 4.3) |
| Swelling: Mild | 0.5 (0.0 to 2.8) | 0.5 (0.0 to 2.8) |
| Swelling: Moderate | 0.5 (0.0 to 2.8) | 1.0 (0.1 to 3.6) |
| Swelling: Severe | 0.5 (0.0 to 2.8) | 0.0 (0.0 to 1.8) |
| Pain at the injection site: Any | 43.5 (36.5 to 50.7) | 32.0 (25.6 to 38.9) |
| Pain at the injection site: Mild | 33.5 (27.0 to 40.5) | 27.5 (21.4 to 34.2) |
| Pain at the injection site: Moderate | 9.5 (5.8 to 14.4) | 4.0 (1.7 to 7.7) |
| Pain at the injection site: Severe | 0.5 (0.0 to 2.8) | 0.5 (0.0 to 2.8) |
Systemic events included: fever, fatigue, headache, joint pain and muscle pain. Fever was defined as an oral temperature of more than or equal to (\>=)38.0 degree Celsius (C) and was classified as \>=38.0 degree C, \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, joint pain and muscle pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.
| Percentage of participants | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years |
|---|---|---|
| Fever: >= 38.0 degree C | 3.0 (1.1 to 6.4) | 1.5 (0.3 to 4.3) |
| Fever: >=38.0 to 38.4 degree C | 1.5 (0.3 to 4.3) | 0.5 (0.0 to 2.8) |
| Fever: >38.4 to 38.9 degree C | 0 (0.0 to 1.8) | 1.0 (0.1 to 3.6) |
| Fever: >38.9 to 40.0 degree C | 1.5 (0.3 to 4.3) | 0 (0.0 to 1.8) |
| Fever: >40.0 degree C | 0 (0.0 to 1.8) | 0 (0.0 to 1.8) |
| Fatigue: Any | 12.0 (7.8 to 17.3) | 12.0 (7.8 to 17.3) |
| Fatigue: Mild | 7.5 (4.3 to 12.1) | 8.5 (5.0 to 13.3) |
| Fatigue: Moderate | 4.0 (1.7 to 7.7) | 3.0 (1.1 to 6.4) |
| Fatigue: Severe | 0.5 (0.0 to 2.8) | 0.5 (0.0 to 2.8) |
| Headache: Any | 12.0 (7.8 to 17.3) | 11.5 (7.4 to 16.8) |
| Headache: Mild | 9.5 (5.8 to 14.4) | 9.5 (5.8 to 14.4) |
| Headache: Moderate | 2.0 (0.5 to 5.0) | 1.5 (0.3 to 4.3) |
| Headache: Severe | 0.5 (0.0 to 2.8) | 0.5 (0.0 to 2.8) |
| Joint pain: Any | 5.0 (2.4 to 9.0) | 4.0 (1.7 to 7.7) |
| Joint pain: Mild | 3.0 (1.1 to 6.4) | 2.5 (0.8 to 5.7) |
| Joint pain: Moderate | 2.0 (0.5 to 5.0) | 1.0 (0.1 to 3.6) |
| Joint pain: Severe | 0 (0.0 to 1.8) | 0.5 (0.0 to 2.8) |
| Muscle pain: Any | 14.5 (9.9 to 20.2) | 9.0 (5.4 to 13.9) |
| Muscle pain: Mild | 10.0 (6.2 to 15.0) | 7.0 (3.9 to 11.5) |
| Muscle pain: Moderate | 4.5 (2.1 to 8.4) | 1.5 (0.3 to 4.3) |
| Muscle pain: Severe | 0 (0.0 to 1.8) | 0.5 (0.0 to 2.8) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% confidence interval was based on the Clopper and Pearson method.
| Percentage of participants | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Vaccination to 1 Month After Vaccination | 1.5 (0.3 to 4.3) | 3.0 (1.1 to 6.4) |
An SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event.
| Percentage of participants | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination to 1 Month After Vaccination | 0 | 0 |
GMFRs and 2-sided 95% confidence interval (CIs) were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ in the analysis. Evaluable immunogenicity population: Eligible participants in the immunogenicity subset who received 1 dose of the intervention with at least 1 valid immunogenicity result from the blood sample collection within 27 to 49 days after vaccination, had no other major protocol deviations as determined by the clinician.
| Fold rise | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years |
|---|---|---|
| Serotype 1 | 24.3 (17.2 to 34.3) | 17.1 (10.9 to 26.9) |
| Serotype 3 | 8.9 (5.7 to 13.8) | 8.8 (5.6 to 13.8) |
| Serotype 4 | 15.2 (7.7 to 29.8) | 42.6 (22.0 to 82.6) |
| Serotype 5 | 14.9 (8.6 to 25.8) | 24.3 (13.5 to 43.7) |
| Serotype 6A | 29.8 (16.3 to 54.5) | 30.9 (17.5 to 54.7) |
| Serotype 6B | 8.6 (5.0 to 15.0) | 11.6 (6.6 to 20.5) |
| Serotype 7F | 16.0 (9.2 to 27.9) | 24.1 (15.6 to 37.4) |
| Serotype 9V | 4.8 (3.2 to 7.1) | 9.5 (5.7 to 15.8) |
| Serotype 14 | 5.8 (3.5 to 9.9) | 6.0 (3.3 to 10.9) |
| Serotype 18C | 21.4 (11.4 to 40.1) | 42.0 (22.4 to 78.6) |
| Serotype 19A | 15.0 (9.1 to 24.7) | 30.9 (18.1 to 52.6) |
| Serotype 19F | 13.1 (7.3 to 23.5) | 19.1 (10.5 to 35.0) |
| Serotype 23F | 46.2 (21.8 to 98.2) | 53.6 (28.3 to 101.4) |
| Serotype 8 | 18.4 (10.5 to 32.4) | 38.2 (22.8 to 64.2) |
| Serotype 10A | 8.4 (5.0 to 14.0) | 31.1 (16.1 to 59.9) |
| Serotype 11A | 3.3 (2.3 to 4.7) | 9.5 (5.2 to 17.3) |
| Serotype 12F | 76.1 (33.4 to 173.7) | 75.2 (36.7 to 154.0) |
| Serotype 15B | 48.8 (22.2 to 107.0) | 86.2 (40.8 to 182.1) |
| Serotype 22F | 12.6 (7.8 to 20.4) | 30.8 (14.2 to 67.0) |
| Serotype 33F | 8.4 (5.0 to 14.0) | 11.7 (7.3 to 18.6) |
Collected over Systematic assessment: local reactions and systemic events recorded from Day 1 to Day 7 after vaccination; Non-systematic assessment: All-cause mortality, SAEs and other AEs recorded from day of vaccination (Day 1) up to 1 month after vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20vPnC | 0/400 (0%) | 0/400 (0%) | 171/400 (42.8%) |
| Event | 20vPnC |
|---|---|
| Injection site pain (PAIN)General disorders | 151/400 |
| Fatigue (FATIGUE)General disorders | 48/400 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 47/400 |
| Headache (HEADACHE)Nervous system disorders | 47/400 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 18/400 |
| Pyrexia (FEVER)General disorders | 9/400 |
| Injection site swelling (SWELLING)General disorders | 6/400 |
Safety population included all participants who received any study intervention and had safety data assessed after vaccination.
| Age, Continuous(Years) | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years | Total |
|---|---|---|---|
| Mean | 34.7 ± 8.18 | 58.8 ± 7.22 | 46.7 ± 14.31 |
| Sex: Female, Male(Participants) | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years | Total |
|---|---|---|---|
| Female | 64 | 52 | 116 |
| Male | 136 | 148 | 284 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 200 | 200 | 400 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: 18 to 49 Years | Cohort 2: >= 50 Years | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 200 | 200 | 400 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2023 to primary completion in Oct 2023, 1 month.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 1 month is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine